Home / Health / FDA Launches AI to Track Product Side Effects in Real Time
FDA Launches AI to Track Product Side Effects in Real Time
11 Mar
Summary
- New AI platform, AEMS, launched Tuesday by the FDA.
- AEMS consolidates outdated systems, saving $120 million over five years.
- AI assists in data entry, aiming to capture 80% more adverse event reports.
The Food and Drug Administration (FDA) has introduced a new artificial intelligence-powered platform, the FDA Adverse Event Monitoring System (AEMS), which commenced operations on Tuesday. This initiative consolidates multiple legacy systems, including FAERS, VAERS, and AERS, into a single, intuitive platform for tracking adverse events. AEMS is designed to streamline the public reporting of unexpected health effects associated with medicines, vaccines, cosmetics, and other consumer products.
The agency anticipates that AEMS will save taxpayers an estimated $120 million over the next five years, a significant improvement from the current $37 million annual cost of managing seven separate databases. Artificial intelligence will be employed to assist with manual data entries and the coding of adverse events. This technological transformation aims to capture approximately 80% of reports that were previously lost due to complex filing procedures, thereby enhancing the agency's post-market surveillance capabilities.
Consumers and researchers will benefit from real-time access to key data, a marked improvement over the current quarterly reports. A pilot program for AEMS saw a 3000% increase in user engagement. Future phases will focus on implementing a user-friendly front-end system for easier report submission, further improving the completeness of adverse event data collection.
